N/A
Manufactured by NextWave Pharmaceuticals, Inc
24,180 FDA adverse event reports analyzed
Last updated: 2026-04-15
CLONIDINE HYDROCHLORIDE is a medication tracked in the FDA Adverse Event Reporting System (FAERS), manufactured by NextWave Pharmaceuticals, Inc. The most commonly reported adverse reactions for CLONIDINE HYDROCHLORIDE include HYPERTENSION, HEADACHE, FATIGUE, OFF LABEL USE, PAIN. This page provides a comprehensive breakdown of reported side effects, safety signals, patient demographics, and AI-powered safety analysis for CLONIDINE HYDROCHLORIDE.
Out of 5,066 classified reports for CLONIDINE HYDROCHLORIDE:
The FDA classifies an adverse event as “serious” if it results in death, hospitalization, disability, congenital anomaly, or requires intervention to prevent permanent damage.
Demographics reflect voluntary FDA adverse event reporting patterns and may not represent the full patient population.
This profile reflects 24,180 FDA FAERS reports that mention CLONIDINE HYDROCHLORIDE. Reporting is voluntary and does not prove that the drug caused any listed event.
Frequently reported terms in FAERS include HYPERTENSION, HEADACHE, FATIGUE, OFF LABEL USE, PAIN, DRUG INEFFECTIVE. Rankings reflect reporting volume in this dataset, not confirmed side effect rates in the general population.
Labeling and FAERS entries often list NextWave Pharmaceuticals, Inc in connection with CLONIDINE HYDROCHLORIDE. Always verify the specific product and NDC with your pharmacist.